Lupin Limited Celebrates New Corporate Office Opening in Bridgewater, NJ

Grand Opening of Lupin Limited's New Office in Bridgewater, NJ

On October 28, 2025, global pharmaceutical leader Lupin Limited celebrated the opening of its new corporate offices located at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The inauguration was attended by esteemed figures including Governor Phil Murphy and Somerset County Commissioner Deputy Director Melonie Marano, alongside Lupin executives such as CEO Vinita Gupta and President of U.S. Generics, Spiro Gavaris.

Lupin's expansion in New Jersey reflects its ongoing commitment to enhancing pharmaceutical innovation while actively contributing to the local economy. The new office, sprawling over 18,000 square feet, is designed to facilitate a variety of corporate functions including commercial activities, human resources, finance, legal affairs, marketing, business development, and research and development. This development is not only a testament to Lupin's robust growth but also its dedication to improving the U.S. healthcare system.

Governor Murphy expressed his pride, stating, "Lupin's continued investments in New Jersey, as showcased by this expansion in Bridgewater, are fully aligned with my administration's priorities to strengthen the state's rich pharmaceutical industry, stimulate economic growth, and create skilled jobs for our residents." The presence of an established pharmaceutical player like Lupin enhances New Jersey’s standing as a hub for biopharmaceutical innovation.

Since its initial foray into the New Jersey market in 2016 with the acquisition of a manufacturing facility in Somerset, Lupin has made significant strides in building a comprehensive operational network within the state. CEO Vinita Gupta remarked, "Our operations in New Jersey, including this new corporate office, manufacturing facilities, and research centers, have played an essential role in our expansion across the U.S. This strategic foundation allows us to foster innovation and provide high-quality medications at affordable prices nationwide. We appreciate the support and partnership provided by New Jersey's leadership, which has been crucial for our ongoing development."

Spiro Gavaris added, "Increasing our presence in New Jersey enables us to enhance our operations while expanding our workforce and contributing positively to the community. Currently, our workforce in New Jersey exceeds 300 employees, and we expect this number to grow. The state offers a wealth of talented professionals across the life sciences sector, and we are eager to create opportunities for them."

Deputy Director Melonie Marano commended Lupin's continuous growth, stating, "Lupin has been a cherished member of the Somerset County business community. Their ongoing expansion is a highlight of the exceptional talent and innovative opportunities available in our area. We’re proud to support Lupin and look forward to nurturing our partnership in the future."

In addition to the opening of its Bridgewater office, Lupin remains committed to investing in U.S. facilities. Recently, the company revealed plans to construct a state-of-the-art manufacturing facility in Coral Springs, Florida, fully dedicated to producing critical respiratory therapies. This commitment further solidifies Lupin’s role in the pharmaceutical landscape while ensuring the availability of essential treatments.

Lupin Limited (BSE 500257, NSE LUPIN) operates extensively across more than 100 markets and possesses a focused presence in respiratory care and complex generics within the U.S. Its headquarters in Naples, Florida, is complemented by 15 manufacturing sites and 7 research centers worldwide, including the newly inaugurated Bridgewater office, housing over 24,000 professionals. For more information, visit Lupin's website or follow the company on LinkedIn.